Statements (52)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
recombinant human growth hormone |
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA 1989 |
| gptkbp:ATCCode |
B03XA01
|
| gptkbp:biosimilar |
gptkb:erythropoietin
|
| gptkbp:brand |
gptkb:Eprex
gptkb:Procrit gptkb:Epogen |
| gptkbp:CASNumber |
gptkb:113427-24-0
|
| gptkbp:contraindication |
uncontrolled hypertension
hypersensitivity to epoetin alfa |
| gptkbp:developedBy |
gptkb:Amgen
|
| gptkbp:drugClass |
colony stimulating factor
hematopoietic agent |
| gptkbp:form |
solution for injection
|
| gptkbp:halfLife |
~19–24 hours (SC)
~4–13 hours (IV) |
| https://www.w3.org/2000/01/rdf-schema#label |
epoetin alfa
|
| gptkbp:indication |
anemia in HIV-infected patients
anemia in cancer patients anemia in chronic renal failure anemia in surgery patients |
| gptkbp:legalStatus |
expired
prescription only |
| gptkbp:mechanismOfAction |
stimulates erythropoiesis
binds to erythropoietin receptor |
| gptkbp:molecularWeight |
~30,400 Da
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:producedBy |
gptkb:Chinese_hamster_ovary_cells
|
| gptkbp:product |
gptkb:protein
|
| gptkbp:riskFactor |
increased risk of cardiovascular events
increased risk of tumor progression in some cancers |
| gptkbp:routeOfAdministration |
subcutaneous
intravenous |
| gptkbp:sideEffect |
nausea
headache hypertension arthralgia thromboembolism |
| gptkbp:storage |
2–8°C
|
| gptkbp:UNII |
QGJZ0XQ6XJ
|
| gptkbp:usedFor |
gptkb:anemia
anemia due to chronic kidney disease anemia due to chemotherapy anemia in HIV patients treated with zidovudine to reduce need for allogeneic blood transfusions |
| gptkbp:WHOModelListOfEssentialMedicines |
yes
|
| gptkbp:bfsParent |
gptkb:Erythropoietin
gptkb:erythropoietin |
| gptkbp:bfsLayer |
6
|